February 2005

gli-1 Oncogene Is Highly Expressed in Granulomatous Skin Disorders, Including Sarcoidosis, Granuloma Annulare, and Necrobiosis Lipoidica Diabeticorum

Author Affiliations

Author Affiliations: Departments of Pathology and Laboratory Medicine (Drs Macaron and Cohen) and Dermatology (Drs Chen and Arbiser), and Emory Center for Outcomes Research (Dr Chen), Emory University School of Medicine, Atlanta, Ga; and Department of Health Services Research and Development (Dr Chen) and Division of Dermatology, Atlanta Veterans Affairs Medical Center, Atlanta (Drs Chen and Arbiser).


Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Dermatol. 2005;141(2):259-262. doi:10.1001/archderm.141.2.259

Background  Sarcoidosis, which occurs most commonly in African American women, is a granulomatous multisystem disorder affecting the skin, lungs, and central nervous system. In a previous immunohistochemistry study of keloids, a scar granuloma stained highly positive for glioma-associated oncogene homologue (gli)-1.

Observation  This observation led us to study whether gli-1, one of the vertebrate zinc finger transcription factor genes of the gli superfamily, is expressed in granulomatous skin disorders such as cutaneous sarcoidosis, granuloma annulare (GA), and necrobiosis lipoidica diabeticorum (NLD). Immunohistochemistry studies for gli-1 were performed on biopsy specimens from patients with cutaneous sarcoidosis, GA, and NLD. All sarcoid lesions were highly positive for gli-1 expression, and 75% of the cells demonstrated positivity with a stain intensity of 3 on a scale of 1 to 3. The gli-1 expression was confined to cutaneous granulomas. CD68 staining was highly positive in the sarcoid lesions as well. Similarly, GA and NLD lesions were uniformly positive for gli-1 expression.

Conclusions  We found that gli-1 is inappropriately expressed in granulomatous lesions of the skin such as cutaneous sarcoidosis, GA, and NLD. These findings provide a rationale for clinical trials of inhibitors of gli-1 signaling, including tacrolimus and sizolimus, for the treatment of cutaneous sarcoidosis and other granulomatous disorders of the skin.

Granulomatous disorders of the skin include cutaneous sarcoidosis, granuloma annulare, (GA), and necrobiosis lipoidica diabeticorum (NLD).1 The etiology of these disorders is unknown. Sarcoidosis has been associated with chronic inflammation and has recently been described in patients receiving interferon α and ribavirin, implying that sarcoidosis may be a TH1-type of inflammatory reaction.1,2 Histologically the granulomas may simulate mycobacterial granulomas, but tissue cultures have not evidenced organisms. Sarcoidosis is a common disorder with significant morbidity and mortality, especially pulmonary sarcoidosis. It can simultaneously affect sites as varied as the skin, kidney, heart, and central nervous system, where it may cause diabetes insipidus.35 Treatment of sarcoidosis usually involves long-term systemic treatment with corticosteroids and other potent immunosuppressive agents, with resulting adverse effects. When sarcoidosis affects only the skin it poses a therapeutic dilemma. On the one hand, lesions respond much better to systemic than to topical steroids; on the other, when sarcoidosis is limited to the skin, systemic steroids may cause disproportionate unwanted effects. Other granulomatous disorders such as GA and NLD appear to involve primarily the skin, but they may occur elsewhere in patients with systemic disorders such as diabetes mellitus, hyperlipidemia, and multiple myeloma.6,7 Again, treatment of these disorders is unsatisfactory. Granuloma annulare may resolve spontaneously after several years but NLD is less likely to resolve spontaneously.

In an earlier study, after an anecdotal report that keloids responded to topical tacrolimus, our group reported that keloids expressed high levels of both gli-1 (glioma-associated oncogene homologue) oncogene and inhibitor of gli-1 signaling.8 In that study, we noted strong gli-1 expression in a suture-induced granuloma, and hypothesized that noninfectious granulomas may express gli-1 protein and that these granulomas may be treated with inhibitors of gli-1 signaling.


Paraffin blocks of biopsy samples of 10 cutaneous sarcoidosis, 3 GA, and 5 NLD lesions were stained with antibodies against gli-1 oncogene, as previously performed on keloids.8 Briefly, 5-μm sections of formalin-fixed, paraffin-embedded tissue were tested for the presence of gli-1 using gli-1–specific antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif) with an avidin-biotin complex technique and steam heat–induced antigen retrieval in a 1:20 ratio. An avidin-biotinylated enzyme complex kit (Dako LSAB2, Dako Corp, Carpinteria, Calif) was used in combination with the automated Dako Autostainer. Hematoxylin was used as a counterstain. Sarcoid lesions were stained with CD68 as well. The staining was done using an avidin-biotin–complex technique with pressure cooker heat–induced antigen retrieval and a Dako Autostainer. The percentage and intensity of positivity for gli-1 and CD68 were microscopically quantitated and recorded. The intensity of positivity was recorded on a 3-tiered scale graduated from 0 to 3 and the intensity of staining was recorded on a 4-tiered scale as follows: 0% to 5%, 0; 6% to 25%, 1; 26% to 50%, 2; 51% to 75%, 3; and 76% to 100%, 4. Statistical analyses were performed with the statistical package SPSS (SPSS Inc, Chicago, Ill).


All cutaneous sarcoid lesions showed high-level gli-1 expression in nearly all cells (Figure 1). Staining was predominantly cytoplasmic, similar to what has been observed in basal cell carcinoma. Cutaneous sarcoids also demonstrated strong expression for CD68, which is consistent with the known strong expression of CD68 in this disorder (Figure 2). Strong gli-1 expression was also observed in lesions of GA (Figure 3) and NLD (Figure 4), ie, to areas of granulomas. There was no difference in intensity of staining between the 3 granulomatous disorders (Table). While there were differences between the 3 disorders in the percentage of cells that stained for gli-1, the difference was not significant (P = .24 by analysis of variance).

Figure 1.
Image not available

Cutaneous sarcoid lesion showing strong intensity and pattern of gli-1 staining (hematoxylin-eosin, original magnification ×10 [A] and ×20 [B]).

Figure 2.
Image not available

Cutaneous sarcoid lesion showing strong intensity and pattern of KP-1 staining (hematoxylin-eosin, original magnification ×10 [A] and ×10 [B]).

Figure 3.
Image not available

Granuloma annulare lesion showing gli-1 staining pattern (hematoxylin-eosin, original magnification ×10 [A] and ×10 [B]).

Figure 4.
Image not available

Necrobiosis lipoidica diabeticorum lesion showing strong intensity and pattern of gli-1 staining (hematoxylin-eosin, original magnification ×10 [A] and ×10 [B]).

Image not available
Summary of Results of gli-1 Staining Pattern in Sarcoid, Granuloma Annulare (GA), and Necrobiosis Lipoidica Diabeticorum (NLD) Lesions

An oncogene that was initially characterized as a gene amplified in a human glioma, gli-1, hence the name gli-1, has been shown to transform cells in culture, and, more recently, to be involved in the pathogenesis of basal cell carcinoma.4 A transcriptional activator, gli-1 is down-regulated by the PATCHED (PTC) gene, which is a receptor for the protein sonic hedgehog (Shh). The PTC gene represses gli-1 transcription, and when PTC is absent, as in basal cell nevus syndrome or sporadic basal cell carcinoma, gli-1 transcription is stimulated. Indeed, transgenic overexpression of gli-1 in mice leads to diffuse development of basal cell carcinoma.57,9

We have previously found that gli-1 is highly expressed in keloids but not in hypertrophic scars.8 A suture-induced granuloma also stained positively for gli-1, suggesting that granulomas may also express gli-1. Mesenchymal cells in keloids have been shown to express CD68,10,11 a marker also commonly observed in granulomatous skin disease, suggesting that gli-1 may be expressed in granulomas as well as keloids. To determine whether this was the case, we stained specimens of cutaneous sarcoidosis, GA, and NLD. All specimens of granulomatous skin disorders stained strongly positive for gli-1. These results demonstrate a rationale for the use of inhibitors of gli-1 signaling, such as topical tacrolimus, in the treatment of granulomatous skin disorders. Indeed, a case report of a patient responding to tacrolimus (Protopic) for cutaneous sarcoidosis has been described.12 Further clinical trials of topical tacrolimus and other inhibitors of gli-1 signaling are warranted for the treatment of sarcoidosis, GA, and NLD.

Back to top
Article Information

Correspondence: Jack L. Arbiser, MD, PhD, Department of Dermatology, Emory University School of Medicine, WMB 5309, 1639 Pierce Dr, Atlanta, GA 30322 (jarbise@emory.edu).

Accepted for Publication: November 4, 2004.

Funding/Support: Dr Arbiser is funded by National Institutes of Health (NIH) grant RO1 AR47901, Bethesda, Md, and Emory Skin Disease Research Core Center grant P30AR42687, Atlanta, Ga. Dr Chen is supported in part by National Institute on Arthritis and Musculoskeletal and Skin Disease Mentored Patient Oriented Career Development Award K23AR02185-01A1, NIH, Bethesda; Emory Skin Disease Research Center grant P30AR42687; and a career development award from the American Skin Association, New York, NY.

Financial Disclosure: None.

Hanno  RCallen  JP Sarcoidosis: a disorder with prominent cutaneous features and their interrelationship with systemic disease Med Clin North Am 1980;64847- 866
Kinzler  KWBigner  SHBigner  DD  et al.  Identification of an amplified, highly expressed gene in a human glioma Science 1987;23670- 73
Nilsson  MUnden  ABKrause  D  et al.  Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1 Proc Natl Acad Sci U S A 2000;973438- 3443
Matise  MPJoyner  AL Gli genes in development and cancer Oncogene 1999;187852- 7859
Grachtchouk  MMo  RYu  S  et al.  Basal cell carcinomas in mice overexpressing Gli2 in skin Nat Genet 2000;24216- 217
Bonifas  JMPennypacker  SChuang  PT  et al.  Activation of expression of hedgehog target genes in basal cell carcinomas J Invest Dermatol 2001;116739- 742
Johnson  RLRothman  ALXie  J  et al.  Human homolog of patched, a candidate gene for the basal cell nevus syndrome Science 1996;2721668- 1671
Kim  ADiCarlo  JCohen  C  et al.  Are keloids really ″gli-loids″? high-level expression of gli-1 oncogene in keloids J Am Acad Dermatol 2001;45707- 711
Aszterbaum  MRothman  AJohnson  RL  et al.  Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome J Invest Dermatol 1998;110885- 888
Horny  HPSchaumburg-Lever  GBolz  SGeerts  MLKaiserling  E Use of monoclonal antibody KP1 for identifying normal and neoplastic human mast cells J Clin Pathol 1990;43719- 722
Fan  HOro  AEScott  MPKhavari  PA Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog Nat Med 1997;3788- 792
Katoh  NMihara  HYasuno  H Cutaneous sarcoidosis successfully treated with topical tacrolimus Br J Dermatol 2002;147154- 156